- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
30 result(s) found for: Environmental health.
Displaying page 1 of 2.
EudraCT Number: 2021-003588-85 | Sponsor Protocol Number: PSYCHIC | Start Date*: 2022-01-11 |
Sponsor Name:UCLouvain | ||
Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ? | ||
Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002708-13 | Sponsor Protocol Number: SP002 | Start Date*: 2004-12-27 | |||||||||||
Sponsor Name:Synergia Pharma, Inc. | |||||||||||||
Full Title: A RANDOMIZED, BLINDED, CROSSOVER TRIAL OF A SINGLE DOSE OF ORAL L-DOPS 300 MG IN AN ENVIRONMENTAL EXPOSURE UNIT IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS | |||||||||||||
Medical condition: seasonal allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003340-37 | Sponsor Protocol Number: PJ21069 | Start Date*: 2018-10-30 | |||||||||||
Sponsor Name:Technological University Dublin | |||||||||||||
Full Title: Efficacy and Mechanisms of Low Dose Atropine in the Control of Myopia in Children Trial name: Myopia Outcome Study of Atropine in Children (MOSAIC) | |||||||||||||
Medical condition: Myopia- a refractive error due to a discrepancy between the anatomical axial length and the focal length of the eye. resulting in distant objects appearing blurred | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001507-76 | Sponsor Protocol Number: BRONCHIOLE2017 | Start Date*: 2017-09-20 |
Sponsor Name:Region Örebro län | ||
Full Title: Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) A pragmatic clinical trial with partial registry-based follow-up | ||
Medical condition: Chronic Obstructive Pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002394-59 | Sponsor Protocol Number: P142 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital | |||||||||||||
Full Title: Medical Cannabis for fibromyalgia - The CANNFIB trial Protocol for a randomized, double-blind, placebo-controlled, parallelgroup, single-center trial | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004044-28 | Sponsor Protocol Number: AKF-396 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Flucloxacillin as an inducer of CYP-enzymes | |||||||||||||
Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003814-37 | Sponsor Protocol Number: AKF-400 | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Odense University Hosipital | |||||||||||||
Full Title: The effect of dicloxacillin on oral absorption of drugs | |||||||||||||
Medical condition: Healthy volunteers. (Dicloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by dicloxacillin. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004262-34 | Sponsor Protocol Number: MM09-SIT-023 | Start Date*: 2020-04-28 | |||||||||||||||||||||
Sponsor Name:Inmunotek, S.L. | |||||||||||||||||||||||
Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an... | |||||||||||||||||||||||
Medical condition: House dust mites allergy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000309-10 | Sponsor Protocol Number: CHUBX2017/45 | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Phase II/III double-blind randomized placebo-controlled trial assessing the preventive effect of Clopidogrel on the systemic sclerosis development risk in subjects with specific dysimmunity and Ray... | |||||||||||||
Medical condition: Raynaud phenomenon | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004216-22 | Sponsor Protocol Number: C602 | Start Date*: 2019-09-25 | |||||||||||
Sponsor Name:Soleno Therapeutics UK Ltd. | |||||||||||||
Full Title: An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome | |||||||||||||
Medical condition: Hyperphagia associated with Prader-Willi Syndrome (PWS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002277-22 | Sponsor Protocol Number: AMYPAD-02 | Start Date*: 2018-09-12 |
Sponsor Name:Stichting VUmc | ||
Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im... | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004905-29 | Sponsor Protocol Number: CCSJ117A12201C | Start Date*: 2020-12-28 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients ≥18 years of ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) BG (Prematurely Ended) FR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000927-29 | Sponsor Protocol Number: NL60405.100.17 | Start Date*: 2017-07-31 |
Sponsor Name:Catharina Ziekenhuis | ||
Full Title: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a mult... | ||
Medical condition: Isolated unresectable colorectal peritoneal metastases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001771-35 | Sponsor Protocol Number: FFR104503 | Start Date*: 2005-10-04 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aque... | ||
Medical condition: Perennial Allergic Rhinitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001556-11 | Sponsor Protocol Number: 1058 | Start Date*: 2011-05-23 | ||||||||||||||||
Sponsor Name:IRCCS FONDAZIONE STELLA MARIS | ||||||||||||||||||
Full Title: Decline of mentale functions in adults with Down Syndrome: clinical and experimental study on the effects of treatment with fluoxetine and of cognitive and physical training. | ||||||||||||||||||
Medical condition: Adults (over 30 years) with Down Syndrome. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002477-22 | Sponsor Protocol Number: R1908-1909-ALG-1703 | Start Date*: 2019-01-25 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY IN CAT-ALLERGIC PATIENTS WITH ASTHMA TO EVALUATE THE EFFICACY OF A SINGLE DOSE OF REGN1908-1909 TO REDUCE BRONCHOCONSTR... | ||||||||||||||||||
Medical condition: Cat-allergic asthma and Bronchoconstriction Upon Cat Allergen Challenge | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002701-94 | Sponsor Protocol Number: FUN-PIR-2020-01 | Start Date*: 2021-08-13 | ||||||||||||||||
Sponsor Name:Fundación para la Gestión de la Investigación Biomédica de Cádiz | ||||||||||||||||||
Full Title: Pirfenidone for the reduction of pulmonary inflammatory and fibrogenic activity in patients with silicosis due to artificial stone and progressive massive fibrosis. | ||||||||||||||||||
Medical condition: progressive massive fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001955-11 | Sponsor Protocol Number: AP105162012 | Start Date*: 2013-12-26 |
Sponsor Name:Psicofundación. Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicología | ||
Full Title: A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial | ||
Medical condition: Emotional disorders specified as anxiety disorders (e.g., panic disorder, generalized anxiety disorder, social phobia, specific phobia), mood disorders (e.g., major depressive disorder, dysthymia),... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004666-14 | Sponsor Protocol Number: CACZ885A2206 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003751-10 | Sponsor Protocol Number: DRI15103 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
